Ignite Creation Date:
2024-05-05 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00267215
Status:
COMPLETED
Last Update Posted:
2012-05-21
First Post:
2005-12-16
Brief Title:
Efficacy and Safety of Lumiracoxib
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A One-week Multicenter Multiple-dose Randomized Double-blind Double-dummy Parallel-group Comparison of the Analgesic Efficacy and Safety of Lumiracoxib COX189 Celecoxib and Placebo in the Treatment of Osteoarthritis of the Knee
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial assessed the safety and efficacy of a single dose of lumiracoxib 400 mg compared to placebo and to a single dose of celecoxib 200mg It also assessed safety and efficacy of 400mg lumiracoxib administered once a day for 7 days compared to placebo and to 200 mg celecoxib twice daily
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None